Literature DB >> 10933703

Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

N M Chapman1, K S Kim, S Tracy, J Jackson, K Höfling, J S Leser, J Malone, P Kolbeck.   

Abstract

We cloned the sequence encoding murine interleukin-4 (mIL-4), including the secretory signal, into the genome of CVB3/0, an artificially attenuated strain of coxsackievirus B3, at the junction of the capsid protein 1D and the viral protease 2Apro. Two strains of chimeric CVB3 were constructed using, in one case, identical sequences to encode 2Apro cleavage sites (CVB3/0-mIL4/47) on either side of the inserted coding sequence and, in the other case, nonidentical sequences that varied at the nucleotide level without changing the amino acid sequences (CVB3-PL2-mIL4/46). Transfection of HeLa cells yielded progeny viruses that replicated with rates similar to that of the parental CVB3/0 strain, although yields of mIL-4-expressing strains were approximately 10-fold lower than those of the parental virus. Western blot analysis of viral proteins isolated from HeLa cells inoculated with either strain of chimeric virus demonstrated that the chimeric viruses synthesized capsid protein 1D at approximately twofold-higher levels than the parental virus. mIL-4 protein was detected by enzyme-linked immunosorbent assay (ELISA) in HeLa cells inoculated with either strain of chimeric virus. Lysates of HeLa cells inoculated with either chimeric virus induced the proliferation of the mIL-4-requiring murine MC-9 cell line, demonstrating biological activity of the CVB3-expressed mIL-4. Reverse transcription (RT)-PCR analysis of viral RNA derived from sequential passaging of CVB3/0-mIL4/47 in HeLa cells demonstrated deletion of the mIL-4 coding sequence occurring by the fourth passage, while similar analysis of CVB3-PL2-mIL4/46 RNA demonstrated detection of the mIL-4 coding sequence in the virus population through 10 generations in HeLa cells. mIL-4 protein levels determined by ELISA were consistent with the stability and loss data determined by RT-PCR analysis of the passaged viral genomes. Studies of insert stability of CVB3-PL2-mIL4/46 during replication in mice showed the presence of the viral mIL-4 insert in pancreas, heart, and liver at 14 days postinfection. Comparison of the murine antibody responses to CVB3-PL2-mIL4/46 and the parental CVB3/0 strain demonstrated an increased level of CVB3-binding serum immunoglobulin G1 in mice inoculated with CVB3-PL2-mIL4/46.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933703      PMCID: PMC112326          DOI: 10.1128/jvi.74.17.7952-7962.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: regulation in response to cell density.

Authors:  S D Carson; J T Hobbs; S M Tracy; N M Chapman
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice.

Authors:  S Tracy; K Höfling; S Pirruccello; P H Lane; S M Reyna; C J Gauntt
Journal:  J Med Virol       Date:  2000-09       Impact factor: 2.327

3.  A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.

Authors:  A Zhang; S C Geisler; A D Smith; D A Resnick; M L Li; C Y Wang; D J Looney; F Wong-Staal; E Arnold; G F Arnold
Journal:  Biol Chem       Date:  1999-03       Impact factor: 3.915

Review 4.  Coxsackieviruses and pancreatitis.

Authors:  A I Ramsingh
Journal:  Front Biosci       Date:  1997-08-15

5.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response.

Authors:  M J Novak; L E Smythies; S A McPherson; P D Smith; C D Morrow
Journal:  Vaccine       Date:  1999-05-14       Impact factor: 3.641

7.  Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities.

Authors:  F Lee; T Yokota; T Otsuka; P Meyerson; D Villaret; R Coffman; T Mosmann; D Rennick; N Roehm; C Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  Treatment of experimental viral myocarditis with interleukin-10.

Authors:  R Nishio; A Matsumori; T Shioi; H Ishida; S Sasayama
Journal:  Circulation       Date:  1999-09-07       Impact factor: 29.690

9.  Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity.

Authors:  S Crotty; B L Lohman; F X Lü; S Tang; C J Miller; R Andino
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

View more
  11 in total

1.  A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.

Authors:  M Dan; J K Chantler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.

Authors:  A Henke; R Zell; G Ehrlich; A Stelzner
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  5'-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA.

Authors:  K-S Kim; S Tracy; W Tapprich; J Bailey; C-K Lee; K Kim; W H Barry; N M Chapman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro.

Authors:  Ralph Feuer; Ignacio Mena; Robb Pagarigan; Mark K Slifka; J Lindsay Whitton
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 5.  Coxsackievirus B3-Its Potential as an Oncolytic Virus.

Authors:  Anja Geisler; Ahmet Hazini; Lisanne Heimann; Jens Kurreck; Henry Fechner
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

6.  An attenuated coxsackievirus b3 vector: a potential tool for viral tracking study and gene delivery.

Authors:  Jun Zeng; Xiao xuan Chen; Jian ping Dai; Xiang feng Zhao; Gang Xin; Yun Su; Ge fei Wang; Rui Li; Yin xia Yan; Jing hua Su; Yu xue Deng; Kang sheng Li
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

Review 7.  Therapeutic Use of Native and Recombinant Enteroviruses.

Authors:  Jani Ylä-Pelto; Lav Tripathi; Petri Susi
Journal:  Viruses       Date:  2016-02-23       Impact factor: 5.048

8.  Attenuated strain of CVB3 with a mutation in the CAR-interacting region protects against both myocarditis and pancreatitis.

Authors:  Ninaad Lasrado; Arunakumar Gangaplara; Chandirasegaran Massilamany; Rajkumar Arumugam; Allison Shelbourn; Mahima T Rasquinha; Rakesh H Basavalingappa; Gustavo Delhon; Shi-Hua Xiang; Asit K Pattnaik; David Steffen; Jay Reddy
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

9.  Expression and stability of foreign epitopes introduced into 3A nonstructural protein of foot-and-mouth disease virus.

Authors:  Pinghua Li; Xingwen Bai; Yimei Cao; Chenghao Han; Zengjun Lu; Pu Sun; Hong Yin; Zaixin Liu
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.

Authors:  Yanzhen Lin; Wei Wang; Junkai Wan; Ying Yang; Wenkun Fu; Dequan Pan; Linli Cai; Tong Cheng; Xiumin Huang; Yifeng Wang
Journal:  Virol J       Date:  2018-04-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.